Lexicon Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LXRX research report →
Companywww.lexpharma.com
Lexicon Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain.
- CEO
- Michael S. Exton
- IPO
- 2000
- Employees
- 103
- HQ
- The Woodlands, TX, US
Price Chart
Valuation
- Market Cap
- $977.23M
- P/E
- -33.67
- P/S
- 14.00
- P/B
- 4.33
- EV/EBITDA
- -48.82
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.07%
- Op Margin
- -34.79%
- Net Margin
- -37.46%
- ROE
- -18.64%
- ROIC
- -9.30%
Growth & Income
- Revenue
- $49.80M · 60.24%
- Net Income
- $-50,341,000 · 74.88%
- EPS
- $-0.14 · 77.78%
- Op Income
- $-48,911,000
- FCF YoY
- 62.27%
Performance & Tape
- 52W High
- $2.53
- 52W Low
- $0.54
- 50D MA
- $1.77
- 200D MA
- $1.43
- Beta
- 0.97
- Avg Volume
- 2.67M
Get TickerSpark's AI analysis on LXRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 30, 26 | Artal Participations S.a r.l. | other | 20,421,735 |
| Apr 30, 26 | Artal Participations S.a r.l. | other | 408,434.7 |
| Apr 30, 26 | Artal Participations S.a r.l. | other | 408,434.7 |
| May 1, 26 | Amouyal Philippe | other | 43,478 |
| May 1, 26 | Amouyal Philippe | other | 35,714 |
| May 1, 26 | SOBECKI CHRISTOPHER J | other | 43,478 |
| May 1, 26 | SOBECKI CHRISTOPHER J | other | 35,714 |
| May 1, 26 | BARKER SAM L | other | 43,478 |
| May 1, 26 | BARKER SAM L | other | 35,714 |
| May 1, 26 | Cheung Ivan | other | 43,478 |
Our LXRX Coverage
We haven't published any research on LXRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LXRX Report →